The medication Anakinra is given through subcutaneous injection (an injection under the skin) for 7 days. The treatment involves daily doses of 100 mg of the medication. Some patients will receive sodium chloride solution as a placebo treatment instead of the active medication.

The study monitors how well the heart functions after starting the treatment, particularly focusing on the heart’s ability to pump blood effectively. The research team will track the children’s progress for up to 6 months after treatment begins, checking their heart function and watching for any side effects that might occur during the treatment period.

The purpose of the study is to evaluate the effectiveness of these treatments in improving the health of patients with fulminant myocarditis. Participants in the study will receive either the active treatments or a placebo. The study will monitor the participants over a period of 28 days to assess outcomes such as survival, the need for heart transplantation, or the use of devices that assist heart function. The study will also track the number of days participants are alive without needing additional heart support.

Throughout the study, participants will receive the treatments intravenously, meaning the medication will be administered directly into a vein. The study aims to gather information on how these treatments affect heart function and overall health, including any side effects that may occur. The results will help determine the best approach to treating fulminant myocarditis and improving patient outcomes.

The purpose of the study is to determine if Ibuprofen is more effective than Paracetamol in treating Acute Myocarditis, particularly in patients whose heart is still functioning well. Participants will be given either Ibuprofen or Paracetamol for a period of three weeks. The study will monitor changes in the heart over a six-month period using a special imaging technique called Cardiac Magnetic Resonance (CMR), which helps visualize the heart’s structure and function.

Throughout the study, participants will undergo regular check-ups to assess their heart health and any changes in their condition. The goal is to see if Ibuprofen can reduce the inflammation in the heart more effectively than the conventional treatment. This research aims to provide valuable insights into better treatment options for those affected by Acute Myocarditis.

Participants in the study will receive either colchicine or a placebo, which is a substance with no active medication. The study will last for about six months, during which time the effects of colchicine on heart health will be closely monitored. This includes looking at changes in heart muscle damage and any heart-related symptoms or events that occur during the study period. The goal is to determine if colchicine can effectively reduce heart inflammation and improve the condition of patients with acute myocarditis.

Throughout the study, various health markers will be assessed, such as heart function and any side effects related to colchicine. The study will also track any serious health events, like heart failure or the need for heart-related medical procedures. By the end of the study, researchers hope to gather valuable information on whether colchicine can be a beneficial treatment for those suffering from acute myocarditis.

The study will examine patients who have inflammation of the heart muscle and reduced heart function, specifically looking at how well the heart pumps blood. The medications will be given as tablets that are taken by mouth. The treatment period lasts for 12 months, during which patients will receive either the study medications or placebo in addition to their standard heart treatment.

After the initial 12-month treatment period, patients will be monitored for another 12 months to see if the effects of the treatment continue. Throughout the study, various measurements will be taken to check heart function and track how well the treatment is working. The study uses special heart tests to monitor the condition of the heart muscle and measure how effectively it pumps blood.

The purpose of the study is to see if the corticosteroid treatment can improve heart function in patients with acute myocarditis. Participants will be randomly assigned to receive either the Solu-Medrone treatment or the placebo. The study will last for a few days, during which the heart’s function will be monitored using tests like an echocardiogram, which is an ultrasound of the heart. This will help doctors see if the treatment is effective in improving the heart’s ability to pump blood.

Throughout the study, participants will be closely monitored by healthcare professionals to ensure their safety and to observe any changes in their condition. The study aims to provide valuable information on whether corticosteroid therapy can be a beneficial treatment for patients with acute myocarditis, potentially leading to better outcomes for those affected by this condition.

The purpose of this study is to evaluate how effective CardiolRx is in helping the heart recover in patients who have Acute Myocarditis and to ensure that it is safe to use in the proposed doses. The study is designed to compare the effects of CardiolRx with a placebo, which means some participants will receive the active treatment while others will receive an inactive substance. This helps researchers understand the true effects of the treatment.

Participants in the study will take the treatment orally for a period of up to 12 weeks. During this time, their heart health will be monitored using a technique called Cardiac Magnetic Resonance (CMR), which is a type of imaging that provides detailed pictures of the heart. The study aims to measure changes in the heart’s structure and function to determine the impact of CardiolRx on heart recovery. The trial is expected to continue until early 2025.

The purpose of the study is to assess the safety and effectiveness of this corticosteroid therapy in patients with complicated or fulminant acute myocarditis. Participants in the study will receive either the corticosteroid treatment or standard therapy with maximal supportive care. The study will monitor the participants over a period of six months to observe any significant events such as death, heart transplant, or the need for advanced heart support devices.

Throughout the study, various health indicators will be tracked, including heart function and levels of certain proteins in the blood that indicate heart stress. The study aims to determine if the corticosteroid treatment can reduce the occurrence of serious heart-related events compared to standard care. Participants will be closely monitored during their hospital stay and after discharge to ensure their safety and to gather comprehensive data on the treatment’s impact.